Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 7/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 9/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12741682 | 0.81 | BACE1 (0.38) | ACEP2RX7L3MBTL1POLB | |
| SCHEMBL1637934 | 0.80 | P2RX7 (0.51) | ACEP2RX7CAPN1 | |
| SCHEMBL1636164 | 0.80 | P2RX7 (0.51) | ACEP2RX7CAPN1POLB | |
| SCHEMBL3631292 | 0.78 | POLB (0.49) | ACEP2RX7POLB | |
| SCHEMBL3631290 | 0.77 | POLB (0.44) | ACEP2RX7L3MBTL1RIPK1POLB | |
| SCHEMBL290018 | 0.77 | CAPN1 (0.60) | ACECAPN1 | |
| SCHEMBL1638078 | 0.77 | P2RX7 (0.42) | ACEP2RX7L3MBTL1CAPN1RIPK1 | |
| SCHEMBL290019 | 0.77 | CAPN1 (0.60) | ACECAPN1 | |
| SCHEMBL12741673 | 0.77 | GBA1 (0.42) | ACE | |
| SCHEMBL1636773 | 0.76 | ACE (0.54) | ACEP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932282-B2 | Imidazolidine carboxamide derivatives as P2X7 modulators | GLAXO GROUP LIMITED (GB) | 2011-04-26 | — | — | US | disclosed |
| US-20100075968-A1 | Imidazolidine Carboxamide Derivatives as P2X7 Modulators | GLAXO GROUP LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| CN-101679291-A | Imidazolidine carboxamide derivatives as P2X7 modulators | GLAXO GROUP LTD | 2010-03-24 | — | — | CN | disclosed |
| EP-2142512-A2 | IMIDAZOLIDINE CARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS | Glaxo Group Limited (GB) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008119825-A2 | IMIDAZOLIDINE CARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075968-A1 | Imidazolidine Carboxamide Derivatives as P2X7 Modulators | P2RX3, P2RX7, P2RX5 | ACE 2499/4885P2RX7 2/4885L3MBTL1 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.